Targeting Rac1 for the prevention of atherosclerosis among U.S. Veterans with inflammatory bowel disease

References

• Ferri N, Contini A, Bernini SK, et al. Role of small GTPase protein Rac1 in cardiovascular diseases: development of new selective pharmacological inhibitors. J Cardiovasc Pharmacol. 2013;62(5):425–435.
   PubMed Web of Science ®Google Scholar
• Qu MJ, Liu B, Qi YX, et al. Role of Rac and Rho-GDI alpha in the frequency-dependent expression of h1-calponin in vascular smooth muscle cells under cyclic mechanical strain. Ann Biomed Eng. 2008;36(9):1481–1488.
   PubMed Web of Science ®Google Scholar
• Doanes AM, Irani K, Goldschmidt-Clermont PJ, et al. A requirement for rac1 in the PDGF-stimulated migration of fibroblasts and vascular smooth cells. Biochem Mol Biol Int. 1998;45(2):279–287.
   PubMedGoogle Scholar
• Weber DS, Taniyama Y, Rocic P, et al. Phosphoinositide-dependent kinase 1 and p21-activated protein kinase mediate reactive oxygen species-dependent regulation of platelet-derived growth factor-induced smooth muscle cell migration. Circ Res. 2004;94(9):1219–1226.
   PubMed Web of Science ®Google Scholar
• Bond M, Wu YJ, Sala-Newby GB, et al. Rho GTPase, Rac1, regulates Skp2 levels, vascular smooth muscle cell proliferation, and intima formation in vitro and in vivo. Cardiovasc Res. 2008;80(2):290–298.
   PubMed Web of Science ®Google Scholar
• Ono H, Ichiki T, Fukuyama K, et al. cAMP-response element-binding protein mediates tumor necrosis factor-alpha-induced vascular smooth muscle cell migration. Arterioscler Thromb Vasc Biol. 2004;24(9):1634–1639.
   PubMed Web of Science ®Google Scholar
• Bandaru S, Ala C, Ekstrand M, et al. Lack of RAC1 in macrophages protects against atherosclerosis. Plos One. 2020;15(9):e0239284.
   PubMed Web of Science ®Google Scholar
• Williams JW, Huang LH, Randolph GJ. Cytokine circuits in cardiovascular disease. Immunity. 2019;50(4):941–954.
   PubMed Web of Science ®Google Scholar
• Poppe D, Tiede I, Fritz G, et al. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of vav guanosine exchange activity on Rac proteins. J Immunol. 2006;176(1):640–651.
   PubMed Web of Science ®Google Scholar
• Marinkovic G, Hamers AA, De Vries CJ, et al. 6-mercaptopurine reduces macrophage activation and gut epithelium proliferation through inhibition of GTPase Rac1. Inflamm Bowel Dis. 2014;20(9):1487–1495.
   PubMed Web of Science ®Google Scholar
• Marinkovic G, Kroon J, Hoogenboezem M, et al. Inhibition of GTPase Rac1 in endothelium by 6-mercaptopurine results in immunosuppression in nonimmune cells: new target for an old drug. J Immunol. 2014;192(9):4370–4378.
   PubMed Web of Science ®Google Scholar
• Seinen ML, van Nieuw Amerongen GP, De Boer NK, et al. Rac1 as a potential pharmacodynamic biomarker for thiopurine therapy in inflammatory bowel disease. Ther Drug Monit. 2016;38(5):621–627.
   PubMed Web of Science ®Google Scholar
• Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Investig. 2003;111(8):1133–1145.
   PubMed Web of Science ®Google Scholar
• Tang L, Wang H, Ziolo MT. Targeting NOS as a therapeutic approach for heart failure. Pharmacol Ther. 2014;142(3):306–315.
   PubMed Web of Science ®Google Scholar
• Santilli F, D’Ardes D, Davi G. Oxidative stress in chronic vascular disease: from prediction to prevention. Vasc Pharmacol. 2015;74:23–37.
   PubMed Web of Science ®Google Scholar
• Kingery JR, Hamid T, Lewis RK, et al. Leukocyte iNOS is required for inflammation and pathological remodeling in ischemic heart failure. Basic Res Cardiol. 2017;112:2.
   PubMed Web of Science ®Google Scholar
• Combadiere C, Potteaux S, Rodero M, et al. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation. 2008;117(13):1649–1657.
   PubMed Web of Science ®Google Scholar
• Winter C, Silvestre-Roig C, Ortega-Gomez A, et al. Chrono-pharmacological targeting of the CCL2-CCR2 axis ameliorates atherosclerosis. Cell Metab. 2018;28(1):175–82 e5.
   PubMed Web of Science ®Google Scholar
• Boisvert WA, Santiago R, Curtiss LK, et al. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest. 1998;101(2):353–363.
   PubMed Web of Science ®Google Scholar
• Menzin J, Aggarwal J, Boatman B, et al. Ezetimibe use and LDL-C goal achievement: a retrospective database analysis of patients with clinical atherosclerotic cardiovascular disease or probable heterozygous familial hypercholesterolemia. J Manag Care Spec Pharm. 2017;23(12):1270–1276.
   PubMed Web of Science ®Google Scholar
• Shen X, DiMario S, Philip K. Gender disparities in health resource utilization in patients with atherosclerotic cardiovascular disease: a retrospective cross-sectional study. Adv Ther. 2019;36(12):3424–3434.
   PubMed Web of Science ®Google Scholar
• Setodji CM, McCaffrey DF, Burgette LF, et al. The right tool for the job: choosing between covariate-balancing and generalized boosted model propensity scores. Epidemiology. 2017;28(6):802–811.
   PubMed Web of Science ®Google Scholar
• McCaffrey DF, Griffin BA, Almirall D, et al. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med. 2013;32(19):3388–3414.
   PubMed Web of Science ®Google Scholar
• Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41–55.
   Web of Science ®Google Scholar
• Haukoos JS, Lewis RJ. The propensity score. JAMA. 2015;314(15):1637–1638.
   PubMed Web of Science ®Google Scholar
• Ohlsson H, Kendler KS. Applying causal inference methods in psychiatric epidemiology: a review. JAMA Psychiatry. 2020;77(6):637–644.
   PubMed Web of Science ®Google Scholar
• Imai K, van Dyk DA. Causal inference with general treatment regimes. J Am Stat Assoc. 2004;99:854–866.
   Web of Science ®Google Scholar
• Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf. 2007;16(3):241–249.
   PubMed Web of Science ®Google Scholar
• Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167(4):492–499.
   PubMed Web of Science ®Google Scholar